The PI3K inhibitor copanlisib synergizes with sorafenib to induce cell death in hepatocellular carcinoma
Liangtao Ye(LMU Klinikum), Enrico N. De Toni(LMU Klinikum)
Cited by 60
Related Papers
Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma
|NEJM Evidence|2022|1.4k
Phase 3 randomized, open-label, multicenter study of tremelimumab (T) and durvalumab (D) as first-line therapy in patients (pts) with unresectable hepatocellular carcinoma (uHCC): HIMALAYA.
|Journal of Clinical Oncology|2022|398
Combined Hepatocellular-Cholangiocarcinoma: Biology, Diagnosis, and Management
|Liver Cancer|2023|44